Valuentum Exclusive Analysis for the Discerning Investor

Bristol-Myers Squibb Disappoints
Shares of Bristol-Myers Squibb have come under intense selling pressure off the heels of disappointing performance at ASCO. Let’s examine the situation.

May 26, 2017

Alexion’s Executive Departures and an Update from Regeneron Pharma
Image shown above: Performance of Regeneron since the summer of 2013.An executive scandal continues to mar the performance of Alexion Pharmaceuticals. The CFO has resigned his position effective the end of August, but there is more to this story. Let’s also talk Regeneron.

May 17, 2017

Coherus Biosciences Begins the Process of Bringing a Humira Biosimilar to Market
Image Source: Drugs.com. The duration and validity of patents that back the intellectual property of drugs in the pharma/biotech industry underpin the group’s revenue stream. Once patent protection is lost, however, revenue from products typically nosedives as multi-source products come to market, undercutting their original price. The patent estate, in essence, bestows monopoly-like pricing power to Big Pharma. Once lost though, it becomes tough to replace. Let’s provide a quick update on the breaking Coherus Biosciences patent win.

Apr 17, 2017

Which Mid-Stage Biotech Can Grow Into the Next Large Cap Biotech Behemoth?
Image Source: Steven Depolo. The biotech field is on the cutting edge of scientific research. The production of new therapies often positively affects the share price of these innovative companies as long-term revenue and earnings expectations become embedded in the stock price. Let’s take a look at several mid-stage biotechs that may grow into dominant players.

Mar 11, 2017

Celgene: A Hemeoncology Powerhouse
Let’s walk through the investment merits of one of the market darlings in biotech.

Feb 23, 2017

3 Critical Drug Approvals For Your Radar
Image Source: Neurocrine Biosciences. What can investors expect when it comes to imminent drug approvals? Let’s cover three important ones.

Feb 14, 2017

Is AbbVie a Value Trap?
Image Source: Express Scripts. With uncertainty surrounding the patent of blockbuster drug Humira, AbbVie is looking to deliver another success story from its pipeline. Is it headed for a patent cliff? Let’s take a look.

Jan 19, 2017

The Dreaded Patent Cliff: 3 Pharmaceutical Companies at Risk
Image Source: Global Panorama. Let's have a look at 3 pharmaceutical giants that may encounter some troubles in coming years.

Dec 10, 2016

Image: Returns Following the Trump Victory
The stock market is at all-time highs…again. Optimism about what the Trump administration might bring is the main driver, and many are pointing to reduced corporate taxes, translating to higher dividend payments, as reasons to be even more optimistic.

Nov 16, 2016

Pharma, Biotech and How to Consider Investing In It
The Valuentum analyst team digs deep into recent trends in big pharma and biotech from the lofty pricing of drugs to political and competitive pressures to ETF considerations and beyond. ~10 mins.

Valuentum Exclusive Analysis for the Discerning Investor Symbol Keyword

Member Login

Newsletters/Portfolios

Dividend Cushion

Stock Screens

Products & Tools

Value Trap

The Buying Index, VBI

Dividend Changes

Valuentum Exclusive Analysis for the Discerning Investor